CPI 008
Alternative Names: CPI-008; cRGD-ZW800-1; cyclo-(RGDyK)-ZW800-1Latest Information Update: 27 Feb 2026
At a glance
- Originator Curadel Pharma
- Class Diagnostic conjugates; Imaging agents; Peptides
- Mechanism of Action Diagnostic imaging enhancers
-
Orphan Drug Status
Yes - Pancreatic cancer
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Colorectal cancer; Head and neck cancer; Pancreatic cancer
Highest Development Phases
- Phase II Adenocarcinoma; Squamous cell cancer
Most Recent Events
- 20 Jan 2026 CPI 008 is available for licensing as of 20 Jan 2026. https://www.curadelpharma.com/
- 20 Jan 2026 Curadel Pharma completes a phase II trial in Cancer (diagnosis) prior to January 2026 (Curadel Pharma pipeline, January 2026)
- 07 Jan 2026 CPI 008 receives Orphan Drug status for Pancreatic cancer in European Union